Patents by Inventor Cary L. Queen
Cary L. Queen has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Publication number: 20080160018Abstract: Novel methods for producing, and compositions of, humanized immunoglobulins having one or more complementarity determining regions (CDR's) and possible additional amino acids from a donor immunoglobulin and a framework region from an accepting human immunoglobulin are provided. Each humanized immunoglobulin chain will usually comprise, in addition to the CDR's, amino acids from the donor immunoglobulin framework that are, e.g., capable of interacting with the CDR's to effect binding affinity, such as one or more amino acids which are immediately adjacent to a CDR in the donor immunoglobulin or those within about 3 ? as predicted by molecular modeling. The heavy and light chains may each be designed by using any one or all of various position criteria.Type: ApplicationFiled: November 20, 2006Publication date: July 3, 2008Applicant: PDL BioPharma, Inc.Inventors: Cary L. Queen, Man Sung Co, William P. Schneider, Nicholas F. Landolfi, Kathleen L. Coelingh, Harold E. Selick
-
Patent number: 7183390Abstract: The invention provides humanized immunoglobulins that bind to and neutralize ?-interferon. The antibodies are useful for treatment of diseases of the immune system, particularly autoimmune diseases.Type: GrantFiled: November 13, 2001Date of Patent: February 27, 2007Assignee: PDL BioPharma, Inc.Inventors: Maximiliano Vasquez, Nicholas F. Landolfi, Naoya Tsurushita, Cary L. Queen
-
Patent number: 7022500Abstract: Novel methods for producing, and compositions of, humanized immunoglobulins having one or more complementarity determining regions (CDR's) and possible additional amino acids from a donor immunoglobulin and a framework region from an accepting human immunoglobulin are provided. Each humanized immunoglobulin chain will usually comprise, in addition to the CDR's, amino acids from the donor immunoglobulin framework that are, e.g., capable of interacting with the CDR's to effect binding affinity, such as one or more amino acids which are immediately adjacent to a CDR in the donor immunoglobulin or those within about about 3? as predicted by molecular modeling. The heavy and light chains may each be designed by using any one or all of various position criteria.Type: GrantFiled: November 22, 2000Date of Patent: April 4, 2006Assignee: Protein Design Labs, Inc.Inventors: Cary L. Queen, Harold E. Selick
-
Patent number: 6933368Abstract: The present invention provides methods for producing mutationally-altered immunoglobulins and compositions containing such mutationally-altered immunoglobulins, wherein the mutationally-altered immunoglobulins have at least one mutation that alters the pattern of glycosylation in a variable region and thereby modifies the affinity of the immunoglobulin for a preselected antigen. The methods and compositions of the invention provide immunoglobulins that possess increased affinity for antigen. Such glycosylation-altered immunoglobulins are suitable for diagnostic and therapeutic applications.Type: GrantFiled: February 25, 2002Date of Patent: August 23, 2005Assignees: Protein Design Labs, Inc., Memorial Sloan Kettering Cancer CenterInventors: Man Sung Co, David A. Scheinberg, Cary L. Queen
-
Publication number: 20040058414Abstract: Novel methods for producing, and compositions of, humanized immunoglobulins having one or more complementarity determining regions (CDR's) and possible additional amino acids from a donor immunoglobulin and a framework region from an accepting human immunoglobulin are provided. Each humanized immunoglobulin chain will usually comprise, in addition to the CDR's, amino acids from the donor immunoglobulin framework that are, e.g., capable of interacting with the CDR's to effect binding affinity, such as one or more amino acids which are immediately adjacent to a CDR in the donor immunoglobulin or those within about about 3 Å as predicted by molecular modeling. The heavy and light chains may each be designed by using any one or all of various position criteria.Type: ApplicationFiled: May 30, 2003Publication date: March 25, 2004Inventors: Cary L. Queen, Man Sung Co, William P. Schneider, Nicholas F. Landolfi, Kathleen L. Coelingh, Harold E. Selick
-
Publication number: 20040049014Abstract: Novel methods for producing, and compositions of, humanized immunoglobulins having one or more complementarity determining regions (CDR's) and possible additional amino acids from a donor immunoglobulin and a framework region from an accepting human immunoglobulin are provided. Each humanized immunoglobulin chain will usually comprise, in addition to the CDR's, amino acids from the donor immunoglobulin framework that are, e.g., capable of interacting with the CDR's to effect binding affinity, such as one or more amino acids which are immediately adjacent to a CDR in the donor immunoglobulin or those within about about 3 Å as predicted by molecular modeling. The heavy and light chains may each be designed by using any one or all of various position criteria.Type: ApplicationFiled: March 13, 2003Publication date: March 11, 2004Applicant: Protein Design Labs, Inc.Inventors: Cary L. Queen, Man Sung Co, William P. Schneider, Nicholas F. Landolfi, Kathleen L. Coelingh, Harold E. Selick
-
Publication number: 20030229208Abstract: Novel methods for producing, and compositions of, humanized immunoglobulins having one or more complementarity determining regions (CDR's) and possible additional amino acids from a donor immunoglobulin and a framework region from an accepting human immunoglobulin are provided. Each humanized immunoglobulin chain will usually comprise, in addition to the CDR's, amino acids from the donor immunoglobulin framework that are, e.g., capable of interacting with the CDR's to effect binding affinity, such as one or more amino acids which are immediately adjacent to a CDR in the donor immunoglobulin or those within about about 3 Å as predicted by molecular modeling. The heavy and light chains may each be designed by using any one or all of various position criteria.Type: ApplicationFiled: March 13, 2003Publication date: December 11, 2003Applicant: Protein Design Labs, Inc.Inventors: Cary L. Queen, Man Sung Co, William P. Schneider, Nicholas F. Landolfi, Kathleen L. Coelingh, Harold E. Selick
-
Publication number: 20030054497Abstract: The present invention provides methods for producing mutationally-altered immunoglobulins and compositions containing such mutationally-altered immunoglobulins, wherein the mutationally-altered immunoglobulins have at least one mutation that alters the pattern of glycosylation in a variable region and thereby modifies the affinity of the immunoglobulin for a preselected antigen. The methods and compositions of the invention provide immunoglobulins that possess increased affinity for antigen. Such glycosylation-altered immunoglobulins are suitable for diagnostic and therapeutic applications.Type: ApplicationFiled: February 25, 2002Publication date: March 20, 2003Applicant: PROTEIN DESIGN LABS, INC.Inventors: Man Sung Co, David A. Scheinberg, Cary L. Queen
-
Publication number: 20020091240Abstract: The invention provides humanized immunoglobulins that bind to and neutralize &ggr;-interferon. The antibodies are useful for treatment of diseases of the immune system, particularly autoimmune diseases.Type: ApplicationFiled: November 13, 2001Publication date: July 11, 2002Applicant: Protein Design Labs, Inc.Inventors: Maximiliano Vasquez, Nicholas F. Landolfi, Naoya Tsurushita, Cary L. Queen
-
Patent number: 6350861Abstract: The present invention provides methods for producing mutationally-altered immunoglobulins and compositions containing such mutationally-altered immunoglobulins, wherein the mutationally-altered immunoglobulins have at least one mutation that alters the pattern of glycosylation in a variable region and thereby modifies the affinity of the immunoglobulin for a preselected antigen. The methods and compositions of the invention provide immunoglobulins that possess increased affinity for antigen. Such glycosylation-altered immunoglobulins are suitable for diagnostic and therapeutic applications.Type: GrantFiled: May 23, 1997Date of Patent: February 26, 2002Assignees: Protein Design Labs, Inc., Memorial Sloan Kettering Cancer CenterInventors: Man Sung Co, David A. Scheinberg, Cary L. Queen
-
Patent number: 6329511Abstract: The invention provides humanized immunoglobulins that bind to and neutralize &ggr;-interferon. The antibodies are useful for treatment of diseases of the immune system, particularly autoimmune diseases.Type: GrantFiled: November 29, 1999Date of Patent: December 11, 2001Assignee: Protein Design Labs, Inc.Inventors: Maximiliano Vasquez, Nicholas F. Landolfi, Naoya Tsurushita, Cary L. Queen
-
Patent number: 6180370Abstract: Novel methods for producing, and compositions of, humanized immunoglobulins having one or more complementarity determining regions (CDR's) and possible additional amino acids from a donor immunoglobulin and a framework region from an accepting human immunoglobulin are provided. Each humanized immunoglobulin chain will usually comprise, in addition to the CDR's, amino acids from the donor immunoglobulin framework that are, e.g., capable of interacting with the CDR's to effect binding affinity, such as one or more amino acids which are immediately adjacent to a CDR in the donor immunoglobulin or those within about about 3 Å as predicted by molecular modeling. The heavy and light chains may each be designed by using any one or all of various position criteria.Type: GrantFiled: June 7, 1995Date of Patent: January 30, 2001Assignee: Protein Design Labs, Inc.Inventors: Cary L. Queen, Harold E. Selick
-
Patent number: 6051405Abstract: The present invention describes constructs encoding recombinant scFv-toxin fusion proteins which selectively kill cells bearing appropriate antigens or receptors.Type: GrantFiled: April 8, 1992Date of Patent: April 18, 2000Assignees: The United States of America as represented by the Secretary of the Department of Health and Human Services, Protein Design Labs, Inc.Inventors: David FitzGerald, Vijay Kumar Chaudhary, Ira Harry Pastan, Thomas Alexander Waldmann, Cary L Queen
-
Patent number: 6046310Abstract: Fas ligand fusion proteins comprising a polypeptide capable of specifically binding an antigen or a cell surface marker are prepared employing recombinant DNA technology for use in, e.g., treatment of autoimmune disorders.Type: GrantFiled: March 11, 1997Date of Patent: April 4, 2000Assignee: Protein Design Labs., Inc.Inventors: Cary L. Queen, William P. Schneider, Maximiliano Vasquez
-
Patent number: 5863745Abstract: The present invention describes recombinant antibody toxin fusion proteins which selectively kill cells bearing appropriate antigens or receptors.Type: GrantFiled: June 5, 1995Date of Patent: January 26, 1999Assignee: The United States of America as represented by the Department of Health and Human ServicesInventors: David J. Fitzgerald, Vijay Kumar Chaudhary, Ira H. Pastan, Thomas Alexander Waldmann, Cary L. Queen
-
Patent number: 5714350Abstract: The present invention provides methods for producing mutationally-altered immunoglobulins and compositions containing such mutationally-altered immunoglobulins, wherein the mutationally-altered immunoglobulins have at least one mutation that alters the pattern of glycosylation in a variable region and thereby modifies the affinity of the immunoglobulin for a preselected antigen. The methods and compositions of the invention provide immunoglobulins that possess increased affinity for antigen. Such glycosylation-altered immunoglobulins are suitable for diagnostic and therapeutic applications.Type: GrantFiled: January 13, 1995Date of Patent: February 3, 1998Assignees: Protein Design Labs, Inc., Sloan-Kettering Cancer CenterInventors: Man Sung Co, David A. Scheinberg, Cary L. Queen
-
Patent number: 5696237Abstract: The present invention describes recombinant antibody toxin fusion proteins which selectively kill cells bearing appropriate antigens or receptors.Type: GrantFiled: June 5, 1995Date of Patent: December 9, 1997Assignee: The United States of America as represented by the Department of Health and Human ServicesInventors: David FitzGerald, Vijay Kumar Chaudhary, Ira Harry Pastan, Thomas Alexander Waldmann, Cary L. Queen
-
Patent number: 5693761Abstract: Novel methods for producing, and compositions of, humanized immunoglobulins having one or more complementarity determining regions (CDR's) and possible additional amino acids from a donor immunoglobulin and a framework region from an accepting human immunoglobulin are provided. Each humanized immunoglobulin chain will usually comprise, in addition to the CDR's, amino acids from the donor immunoglobulin framework that are, e.g., capable of interacting with the CDR's to effect binding affinity, such as one or more amino acids which are immediately adjacent to a CDR in the donor immunoglobulin or those within about about 3 .ANG. as predicted by molecular modeling. The heavy and light chains may each be designed by using any one or all of various position criteria.Type: GrantFiled: June 7, 1995Date of Patent: December 2, 1997Assignee: Protein Design Labs, Inc.Inventors: Cary L. Queen, William P. Schneider, Harold E. Selick
-
Patent number: 5693762Abstract: Novel methods for producing, and compositions of, humanized immunoglobulins having one or more complementarity determining regions (CDR's) and possible additional amino acids from a donor immunoglobulin and a framework region from an accepting human immunoglobulin are provided. Each humanized immunoglobulin chain will usually comprise, in addition to the CDR's, amino acids from the donor immunoglobulin framework that are, e.g., capable of interacting with the CDR's to effect binding affinity, such as one or more amino acids which are immediately adjacent to a CDR in the donor immunoglobulin or those within about about 3 .ANG. as predicted by molecular modeling. The heavy and light chains may each be designed by using any one or all of various position criteria.Type: GrantFiled: June 7, 1995Date of Patent: December 2, 1997Assignee: Protein Design Labs, Inc.Inventors: Cary L. Queen, Man Sung Co, William P. Schneider, Nicholas F. Landolfi, Kathleen L. Coelingh, Harold E. Selick
-
Patent number: RE35861Abstract: Method and apparatus for comparing original and modified versions of a document. The system of the present invention utilizes a hash number generator CPU to generate hash numbers for lines and sentences contained in the documents. Matching hash numbers are defined as anchorpoints and stored in an anchorpoint memory. A comparator CPU performs a character-by-character comparison of the respective documents radiating outward from each anchorpoint. This comparison generates identity blocks which are defined as blocks which are the same in both documents. Non-identity blocks are defined as difference blocks and are characterized as insertions or deletions depending on their status. A portion of the original and modified document is displayed in a split-screen format on a display, such as a CRT. Cursors on the top and bottom half of the screen identify corresponding portions of the documents.Type: GrantFiled: May 9, 1996Date of Patent: July 28, 1998Assignee: Advanced Software, Inc.Inventor: Cary L. Queen